Georgia Institute of Technology | United States
Dr. Dipak Walunj is a medicinal chemist specializing in the design and synthesis of anticancer molecular chimeras and bioactive compounds. He earned his Ph.D. in Medicinal Chemistry from Ariel University, Israel, where his research focused on developing anticancer molecular chimeras under the guidance of Prof. Gary Gellerman. He also holds an M.Sc. in Organic Chemistry and a B.Sc. in Chemistry from the University of Pune, India. Currently, Dr. Walunj is a Postdoctoral Fellow at the Georgia Institute of Technology, USA, conducting advanced research on the design, synthesis, and biocharacterization of new deferiprone analogs for treating triple-negative breast cancer. His previous professional roles include Assistant Professor at Nowrosjee Wadia College, Pune, Research Fellow at the University of Milan, and Project Assistant at CSIR–National Chemical Laboratory, Pune, where he contributed to natural product synthesis and drug development. His research interests encompass medicinal chemistry, organic synthesis, anticancer drug design, and chemical biology. Dr. Walunj’s excellence in research has been recognized with several fellowships and the Award of Excellence in Doctoral Research from Ariel University. Through his innovative work, he continues to contribute to the advancement of therapeutic chemistry and cancer drug discovery.
Featured Publication
Walunj, D., Egarmina, K., Zipin-Roitman, A., Muddineni, S. S. N. A., Tkachenko, I., Mitra, P., Tobi, D., Bazylevich, A., Shpilberg, O., Milyavsky, M., Hershkovitz-Rokah, O., & Gellerman, G. (2025). Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia. Scientific Reports,